Adlai Nortye, Omada Health, Syndax, Six Flags, and Immunic Lead Market Declines Several stocks recorded double-digit losses on October 13, 2026. A failed clinical trial drove the decline in Syndax...
Bumble (NASDAQ: BMBL) surged 56.6% after agreein...
Cantor Fitzgerald maintains an Outperform rat...
Gordon Haskett Capital Corporation set a $105 price target for Ollie's Bargain Outlet, indicating an 18.1% upside from its trading price. The company's board approved an additional $500 milli
H.C. Wainwright maintained its Buy rating on AngioDynamics but lowered its price target to $18. AngioDynamics reported a 6.9% revenue increase to $80.9 million and a narrowed adjusted loss of
Domino's Pizza (NASDAQ:DPZ) reported strong Q3 2026 earnings per share of $4.60, surpassing analyst estimates, despite slower revenue growth of 3.4%. Domino's same-store sales growth remained
Citigroup (NYSE: C) reported robust Q3 2026 earnings, surpassing analyst estimates for both EPS and revenue. Exceptional performance in fixed-income trading and services significantly contrib
Differing Q3 2026 earnings and revenue forecasts from Wall Street and Zacks. Strong projected growth in earnings (31.3%), revenue (14%), net interest income (19.8%), and service fees (12.9%).
BioNTech (NASDAQ: BNTX) Clinical Trial Update: BNT113 Misses First Primary Endpoint BioNTech’s investigational mRNA cancer immunotherapy BNT113, combined with pembrolizumab, did not produce a
